Furthermore, PBRM1 mutations have been found to confer a slight increase of death risk, while SETD2 or BAP1 mutations were associated with serious death risks in ccRCC patients [15–17]. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.